Technical Analysis for KROS - Keros Therapeutics, Inc.

Grade Last Price % Change Price Change
B 53.96 -0.53% -0.29
KROS closed down 0.53 percent on Tuesday, December 7, 2021, on 1.65 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical KROS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
New Uptrend Bullish 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish -0.53%
Golden Cross Bullish -0.53%
Lizard Bullish Bullish Day Trade Setup -0.53%
Doji - Bullish? Reversal -0.53%
Lower Bollinger Band Touch Weakness -0.53%
Oversold Stochastic Weakness -0.53%
Older End-of-Day Signals for KROS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 18 hours ago
20 DMA Resistance about 23 hours ago
Up 1 ATR about 23 hours ago
Up 5% about 24 hours ago
Rose Above 10 DMA about 24 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Keros Therapeutics, Inc. Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Bone Rare Diseases Hypertension Disorders Hematology Therapeutic Product Pulmonary Arterial Hypertension Anemia Myelodysplastic Syndrome Syndromes Osteoporosis Genodermatoses Molecule Product Myelodysplastic Syndromes Skeletal Disorders Myelofibrosis Bone Disease Thrombocytopenia Blood Disorders Hematopathology Musculoskeletal Disorders

Is KROS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 86.8
52 Week Low 28.5
Average Volume 158,456
200-Day Moving Average 47.60
50-Day Moving Average 47.86
20-Day Moving Average 57.97
10-Day Moving Average 55.32
Average True Range 3.47
ADX 31.82
+DI 22.72
-DI 16.57
Chandelier Exit (Long, 3 ATRs) 53.07
Chandelier Exit (Short, 3 ATRs) 61.35
Upper Bollinger Bands 64.06
Lower Bollinger Band 51.88
Percent B (%b) 0.17
BandWidth 21.01
MACD Line 1.60
MACD Signal Line 2.91
MACD Histogram -1.3101
Fundamentals Value
Market Cap 1.25 Billion
Num Shares 23.2 Million
EPS -99999.99
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 613.65
Price-to-Book 13.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 60.41
Resistance 3 (R3) 61.10 59.63 59.34
Resistance 2 (R2) 59.63 57.99 59.29 58.98
Resistance 1 (R1) 56.80 56.98 56.07 56.11 58.62
Pivot Point 55.33 55.33 54.97 54.99 55.33
Support 1 (S1) 52.50 53.69 51.77 51.81 49.30
Support 2 (S2) 51.03 52.68 50.69 48.94
Support 3 (S3) 48.20 51.03 48.59
Support 4 (S4) 47.51